The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation.
N 6-Methyladenosine (m6A) is the most abundant RNA modification in mammal mRNAs and increasing...
Read More
Hematology/Oncology
Proteomic analysis of degradation ubiquitin signaling by ubiquitin occupancy changes responding to 26S proteasome inhibition.
Ubiquitination is a post-translational modification where ubiquitin is covalently attached to...
Read More
Genomic Signatures of Immune Activation Predict Outcome in Advanced Stages of Ovarian Cancer and Basal-Like Breast Tumors.
There is an unmet need for new therapies in metastatic ovarian cancer and basal-like breast cancer...
Read More
Muscle loss during primary debulking surgery and chemotherapy predicts poor survival in advanced-stage ovarian cancer.
Sarcopenia is commonly observed in patients with advanced-stage epithelial ovarian cancer (EOC)....
Read More
Identification three LncRNA prognostic signature of ovarian cancer based on genome-wide copy number variation.
Ovarian cancer is one of the most common malignant tumors of the female reproductive system, which...
Read More
Overcoming Resistance to Platinum-Based Drugs in Ovarian Cancer by Salinomycin and Its Derivatives-An In Vitro Study.
Polyether ionophore salinomycin (SAL) and its semi-synthetic derivatives are recognized as very...
Read More
Strong Evidences of the Ovarian Carcinoma Risk in Women after IVF Treatment
In-vitro fertilization (IVF) has been very popular since the birth of the first...
Read More
Should MMMT still be treated with adjuvant taxane-based combination chemotherapy?
Malignant mixed Mullerian tumors of endometrial (MMMT-E) and ovarian (MMMT-O) origin are...
Read More
Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity, and Genomic Predictors of Drug Response.
The use of predictive biomarkers provides potential individualized cancer therapeutic options to...
Read More
PRMT1 Is Recruited via DNA-PK to Chromatin Where It Sustains the Senescence-Associated Secretory Phenotype in Response to Cisplatin.
Protein arginine methyltransferase 1 (PRMT1) is overexpressed in various human cancers and linked...
Read More
Hyperthermic intraperitoneal chemotherapy for ovarian cancer: The heat is on.
Patients with advanced epithelial ovarian cancer have a high incidence of peritoneal disease...
Read More
Treatment of recurrent epithelial ovarian cancer.
The majority of patients with advanced ovarian cancer progress after first-line therapy and...
Read More
Surgery in recurrent ovarian cancer.
Ovarian cancer is one of the most challenging diseases in gynecologic oncology. The presentation...
Read More
New strategies in ovarian cancer treatment.
Insights from basic science dissecting carcinogenesis in the fallopian tube and ovary have led to...
Read More
Hyperthermic intraperitoneal chemotherapy does not improve survival in advanced ovarian cancer.
Despite its widespread use, until recently, there was no randomized evidence for hyperthermic...
Read More